Signature Healthcare Of Elizabethon Rehab & Wellne Medicare and Medicaid Location: 1200 Spruce Lane, Elizabethton, Tennessee 37643 Ratings: Phone: (423) 543-3202 |
Life Care Center Of Elizabethton Medicare and Medicaid Location: 1641 Highway 19e, Elizabethton, Tennessee 37643 Ratings: Phone: (423) 542-4133 |
Hillview Health Center Medicare and Medicaid Location: 1666 Hillview Drive, Elizabethton, Tennessee 37643 Ratings: Phone: (423) 542-5061 |
Ivy Hall Nursing Home Medicare and Medicaid Location: 301 Watauga Ave, Elizabethton, Tennessee 37643 Ratings: Phone: (423) 542-6512 |
Hermitage Health Center Medicare and Medicaid Location: 1633 Hillview Drive, Elizabethton, Tennessee 37643 Ratings: Phone: (423) 543-2571 |
News Archive
Researchers at Cincinnati Children's Hospital Medical Center have identified a master gene that controls the first breath a newborn infant takes. The findings could have implications for treating premature babies and children and adults with lung disease or lung injury.
In this post in the Bill & Melinda Gates Foundation's "Impatient Optimists" blog, Megan Averill and Tricia Petruney, senior technical officers with FHI 360's Global Health, Population and Nutrition Group, and Ward Cates, president emeritus at FHI 360, discuss the "domino effect" of family planning.
A team of researchers from Canada has developed a class of compounds which may help eradicate a neglected tropical disease that is currently hard to kill in its chronic form. The research was published ahead of print in Antimicrobial Agents and Chemotherapy.
The number of women diagnosed with breast cancer per year in the seven major markets is forecast to increase by 13% over the next decade, finds independent healthcare analyst, Datamonitor.* However, in Japan, breast cancer incidence rates will rise by approximately 24% to 2019 to reach 56,400 cases, compared to 45,600 cases in 2010.
MedivirAB is an emerging researchbased specialty pharmaceutical company focused on infectious diseases. Medivir today announced that its investigational protease inhibitor TMC435, developed by Tibotec Pharmaceuticals, has successfully completed enrollment of three ongoing global phase 3 trials and further reports that all patients are now on TMC435 or active control treatment.
› Verified 5 days ago